Login to Your Account

Financings NEWS
Theraclone Sciences Inc. and the University of Texas MD Anderson Cancer Center broadened an informal immuno-oncology (IO) relationship in a big way, jointly launching Oncoresponse Inc. to discover and advance therapeutic antibodies against targets identified during the treatment of cancer patients receiving the IO regimens.
SHANGHAI – Suzhou Ribo Life Science Co. Ltd., a Chinese siRNA drug company established in 2007, has raised $20 million in venture capital financing.
LONDON – Pharmalink AB has raised SEK100 million (US$12 million) from existing investors to prepare the ground for phase III development of its lead program, Nefecon, and is shaping up for an IPO in 2016.
More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: